FDA approves Regeneron's antibody for rare immune disease, resolves manufacturing issues for aflibercept - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
The FDA approved Regeneron’s pozelimab, the first treatment for a rare, hereditary immune disease that affects fewer than 100 people worldwide. The monoclonal antibody, to be marketed as Veopoz, is expected to be made available to patients this quarter, a Reg…